Superworth

Alaunos Therapeutics EPS TCRT

Diluted earnings per share by quarter and over the last twelve months, from 2009.

Last 12 months, to Jun 30, 2026
−$1.95
Latest quarter, Q2 FY26
−$0.41
Fiscal year 2025
−$2.25

Alaunos Therapeutics' earnings per share was −$1.95 over the twelve months to Jun 30, 2026.

In its latest quarter, Q2 FY26, it was −$0.41.

Earnings per share over time

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearEPSChange
FY2025−$2.25n/a
FY2024−$2.92n/a
FY2023−$21.99n/a
FY2022−$27.00n/a
FY2021−$55.50n/a
FY2020−$58.50n/a
FY2019−$103.50−178%
FY2018$133.50n/a
FY2017−$81.00n/a
FY2016−$198.00n/a
FY2015−$151.50n/a
FY2014−$46.50n/a
FY2013−$99.00n/a
FY2012−$183.00n/a
FY2011−$151.50n/a

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedEPSOn a year earlierLast 12 months
Q2 FY26−$0.41n/a−$1.95
Q1 FY26−$0.59n/a−$2.17
Q4 FY25−$0.40n/a−$2.25
Q3 FY25−$0.55n/a−$2.31
Q2 FY25−$0.63n/a−$2.46
Q1 FY25−$0.67n/a−$2.54
Q4 FY24−$0.46n/a−$2.92
Q3 FY24−$0.70n/a−$7.36
Q2 FY24−$0.71n/a−$11.96
Q1 FY24−$1.05n/a−$16.74
Q4 FY23−$4.90n/a−$21.99
Q3 FY23−$5.30n/a−$23.09

Against its peers

Companies in Healthcare nearest Alaunos Therapeutics' size, closest first, today.

CompanyEPS, 12 monthsGrowth
TCRTAlaunos Therapeutics−$1.95
NEPHNephros$0.16+33% a year
ATNMActinium Pharmaceuticals$0.36
APTAlpha Pro Tech$0.41+24% a year
Peer median$0.36

What the EPS figure tells you

Net income divided by diluted shares. The denominator of PE.

One-off charges and gains swing it. The TTM view smooths a single odd quarter.

More on Alaunos Therapeutics

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.